Cargando…

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ruolan, Wright, Jonathan, Saggu, Parminder, Ait-Khaled, Mounir, Moodley, Riya, Parry, Chris M., Lutz, Thomas, Podzamczer, Daniel, Moore, Richard, Górgolas Hernández-Mora, Miguel, Kinder, Clifford, Wynne, Brian, van Wyk, Jean, Underwood, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/ https://www.ncbi.nlm.nih.gov/pubmed/37376649 http://dx.doi.org/10.3390/v15061350

Ejemplares similares

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )
por: Osiyemi, Olayemi, et al.
Publicado: (2022)

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
por: Batterham, Rachel L, et al.
Publicado: (2023)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2020)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)
por: Osiyemi, Olayemi, et al.
Publicado: (2021)

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2021)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
por: Walmsley, Sharon, et al.
Publicado: (2015)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
por: Borghetti, Alberto, et al.
Publicado: (2019)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
por: Pedersen, Karen Brorup Heje, et al.
Publicado: (2023)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
por: Lee, Ki Hyun, et al.
Publicado: (2022)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

1267. Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results from the TANGO and SALSA Studies
por: Prakash, Manyu, et al.
Publicado: (2022)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection
por: Cahn, Pedro, et al.
Publicado: (2022)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2023)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023)

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
por: Kabra, Madhusudan, et al.
Publicado: (2023)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial: Erratum
Publicado: (2016)

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO)
por: Wyk, Jean Van, et al.
Publicado: (2021)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016
por: Perez Valero, Ignacio, et al.
Publicado: (2020)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019)

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
por: Dumitrescu, Teodora Pene, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_memf0gq9580nfbccovi3phqmri